Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02466750
Recruitment Status : Recruiting
First Posted : June 9, 2015
Last Update Posted : August 15, 2018
Sponsor:
Information provided by (Responsible Party):
U.S. Army Medical Research and Development Command

Brief Summary:
This study is being conducted to collect safety and immunogenicity data for the WEE vaccine, TSI-GSD 210. Enrollment in this protocol is offered for personnel who enter areas where this virus is used in research or is endemic (an area where this disease process is found to occur frequently).

Condition or disease Intervention/treatment Phase
Western Equine Encephalitis Biological: Western Equine Encephalitis (WEE) Vaccine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus
Actual Study Start Date : December 15, 2015
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Encephalitis

Arm Intervention/treatment
Experimental: Primary vaccine
Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
Biological: Western Equine Encephalitis (WEE) Vaccine
Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92

Experimental: Booster series
Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
Biological: Western Equine Encephalitis (WEE) Vaccine
Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92




Primary Outcome Measures :
  1. Number of adverse events [ Time Frame: Up to 5 years ]
  2. Percentage of subjects who develop titers of ≥ 1:40 as determined by PRNT80 [ Time Frame: Up to 5 years ]
    Immunogenicity data will be collected for all subjects and will be evaluated for all per-protocol subjects. The primary immunogenicity endpoint measurements will be the percentage of per-protocol subjects who develop titers of ≥ 1:40 as determined by PRNT80 after WEE vaccination at each scheduled time point for which blood samples are drawn and over the entire study period to study completion.


Secondary Outcome Measures :
  1. Geometric mean of PRNT80 titers [ Time Frame: Up to 5 years ]
    The geometric mean PRNT80 titers of per-protocol subjects at each scheduled time point for which blood samples are drawn and over the entire study period to study completion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be 18 to 65 years old at time of consent.
  2. Have WEE plaque reduction neutralization 80% titers (PRNT80) < 1:10 for primary series.
  3. Have WEE PRNT80 < 1:40 for booster series.
  4. If female of childbearing potential, must agree to have a urine pregnancy test on the same day before each vaccine. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree to not become pregnant for 3 months after receipt of the last study treatment (vaccination).
  5. Be considered at risk for exposure to WEE virus and who have submitted a Request for IND Vaccines for the WEE vaccine.
  6. Sign and date the approved informed consent document and HIPAA Authorization.
  7. Have in their charts

    1. medical history (including concomitant medications) within 60 days of planned first administration of vaccine
    2. physical examination and laboratory tests within 1 year
    3. previous chest radiograph and electrocardiogram
  8. Be medically cleared for participation by an investigator. (Examinations and/or tests may be repeated at the discretion of the enrolling physician.)
  9. Be willing to return for all follow-up visits.
  10. Agree to report any adverse events (AEs) that may or may not be associated with administration of the vaccine for at least 28 days after administration and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study.
  11. Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of the vaccine.

Exclusion Criteria:

  1. Have completed previous WEE vaccine study as a nonresponder (PRNT80 < 1:40).
  2. Have clinically significant abnormal laboratory results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the PI).
  3. Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg, prednisone) within 1 month before planned administration of the vaccine or with other immunosuppressive therapies within 6 months of planned administration of the vaccine. Other immunosuppressive therapies include all cancer chemotherapeutic agents, drugs to prevent transplant rejection, interferons, monoclonal antibodies, protein kinase inhibitors, methotrexate, TNF (tumor necrosis factor) inhibitors, and any other drug determined to be immunosuppressive by the PI. Current administration of topical, inhalational, or intranasal glucocorticoids is not excluded.
  4. Have a confirmed HIV infection (antibody positivity).
  5. Have a positive pregnancy test or be a breastfeeding female.
  6. Have any known allergies to components of the vaccine:

    formaldehyde eggs neomycin sulfate human serum albumin sodium bisulfite

  7. Have administration of another vaccine or investigational product within 28 days of WEE vaccination.
  8. Have any unresolved AE resulting from a previous immunization.
  9. A medical condition that, in the judgment of the PI, would impact subject safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02466750


Contacts
Layout table for location contacts
Contact: Anthony Cardile, DO 310-619-8833 anthony.p.cardile.mil@mail.mil

Locations
Layout table for location information
United States, Maryland
Special Immunizations Program, USAMRIID Recruiting
Fort Deterick, Maryland, United States, 21702
Contact: Anthony P. Cardile, DO, MAJ    310-619-8833    anthony.p.cardile.mil@mail.mil   
Sponsors and Collaborators
U.S. Army Medical Research and Development Command
Investigators
Layout table for investigator information
Principal Investigator: Anthony Cardile, DO United States Army Medical Research Institute of Infectious Diseases

Layout table for additonal information
Responsible Party: U.S. Army Medical Research and Development Command
ClinicalTrials.gov Identifier: NCT02466750     History of Changes
Other Study ID Numbers: S-13-06
First Posted: June 9, 2015    Key Record Dates
Last Update Posted: August 15, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Encephalitis
Encephalomyelitis, Equine
Encephalomyelitis, Western Equine
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arbovirus Infections
Virus Diseases
Encephalitis, Viral
Central Nervous System Viral Diseases
Alphavirus Infections
Togaviridae Infections
RNA Virus Infections
Infectious Encephalitis
Central Nervous System Infections
Encephalomyelitis
Vaccines
Immunologic Factors
Physiological Effects of Drugs